Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Vertex Pharmaceuticals
(NQ:
VRTX
)
547.33
+19.14 (+3.62%)
Streaming Delayed Price
Updated: 2:13 PM EDT, Aug 19, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Vertex Pharmaceuticals
< Previous
1
2
...
17
18
19
20
21
22
23
24
25
...
76
77
Next >
Is Vertex Pharmaceuticals Stock a Buy in 2025?
↗
January 26, 2025
Via
The Motley Fool
Got $5,000? 2 Top Healthcare Stocks to Buy in 2025 and Hold Forever.
↗
January 25, 2025
Via
The Motley Fool
2 Healthcare Stocks You Can Buy Right Now Before They Surge Even Higher
↗
January 24, 2025
Via
The Motley Fool
MaxCyte: Building the Future of Cell and Gene Therapy Innovation
January 23, 2025
MaxCyte's proprietary Flow Electroporation technology enables companies like Vertex and CRISPR Therapeutics to get FDA approved for their gene-editing therapy.
Via
MarketBeat
Got $1,500? 3 Healthcare Stocks to Buy and Hold Forever
↗
January 21, 2025
Via
The Motley Fool
8 Health Care Stocks Whale Activity In Today's Session
↗
January 20, 2025
Via
Benzinga
How Is The Market Feeling About Vertex Pharmaceuticals?
↗
January 15, 2025
Via
Benzinga
Forecasting The Future: 23 Analyst Projections For Vertex Pharmaceuticals
↗
January 10, 2025
Via
Benzinga
3 Unstoppable Stocks to Buy in 2025
↗
January 18, 2025
Via
The Motley Fool
HHS Challenges Vertex Over Fertility Services Program Tied To Casgevy Gene Therapy, Says Company Is 'Grasping at Straws'
↗
January 16, 2025
HHS challenges Vertex Pharmaceuticals' fertility services program, alleging violations of anti-kickback laws linked to its gene-editing therapy for sickle cell disease.
Via
Benzinga
Vertex's Pain Drug: Big Pharma's Next Major Success?
January 16, 2025
Vertex Pharmaceuticals' innovative pain drug holds significant potential, positioning the company for substantial growth in the expanding market.
Via
MarketBeat
Should You Buy Vertex Pharmaceuticals Stock Hand Over Fist Before Jan. 30?
↗
January 16, 2025
Via
The Motley Fool
Here's How Much $100 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth Today
↗
January 14, 2025
Via
Benzinga
If You Invested $1000 In This Stock 20 Years Ago, You Would Have This Much Today
↗
January 07, 2025
Via
Benzinga
Vertex Pharmaceuticals Sets Sight on Expanding Portfolio with Alyftrek Approval, Pain Treatment Progress, and Diabetes Trials
↗
January 14, 2025
Vertex secures FDA approval for ALYFTREK and expands TRIKAFTA use, advances diabetes and kidney disease therapies, and strengthens its global drug pipeline.
Via
Benzinga
Meet the Innovative Growth Stock That Could Rocket 114% to 152% Higher in 2025, According to a Couple of Wall Street Analysts
↗
January 14, 2025
Via
The Motley Fool
My 3 Highest-Conviction Growth Stocks to Buy in 2025
↗
January 13, 2025
Via
The Motley Fool
Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
January 12, 2025
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Pfizer Is 'Too Low To Sell,' Jim Cramer Says: Recommends Nvidia For Robotics Exposure
↗
January 10, 2025
Pfizer stock is down more than 7% over the past year. The pharma giant is in talks to extend its collaboration with an AI start-up.
Via
Benzinga
Topics
Artificial Intelligence
Vertex and Zai Lab Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan Region and Singapore
January 10, 2025
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
Zai Lab and Vertex Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore
January 10, 2025
From
Zai Lab Limited
Via
Business Wire
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.
↗
January 09, 2025
Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up.
Via
Investor's Business Daily
Topics
Artificial Intelligence
Government
Vertex Grapples With Bearish Chart As Death Cross Emerges
↗
January 07, 2025
Vertex Pharmaceuticals (VRTX) is facing technical challenges, with its stock forming a Death Cross and down 15% in 6 months.
Via
Benzinga
2 Gene-Editing Stocks Positioned for a Strong Comeback in 2025
January 07, 2025
Gene editing is a reality and it has potential to cure hereditary diseases in a single treatment. These 2 stocks are pioneers in the CRISPR/Cas-9 space.
Via
MarketBeat
Why This Beaten-Down Growth Stock Is a No-Brainer Buy on the Dip
↗
December 28, 2024
Via
The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
↗
December 26, 2024
Via
Benzinga
Vertex Pharmaceuticals Stock Is Down 13%. Here's Why You Should Buy the Dip
↗
December 26, 2024
Via
The Motley Fool
Top Stock Reports For T-Mobile, Toyota Motor & Vertex Pharmaceuticals
↗
December 24, 2024
Today's Research Daily features new research reports on 16 major stocks, including T-Mobile US, Inc., Toyota Motor Corp., and Vertex Pharmaceuticals Inc., as well as two micro-cap stocks BK...
Via
Talk Markets
Topics
Stocks / Equities
3 No-Brainer Stocks to Buy on the Latest Sell-Off
↗
December 24, 2024
Via
The Motley Fool
Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13
December 23, 2024
From
Vertex Pharmaceuticals Incorporated
Via
Business Wire
< Previous
1
2
...
17
18
19
20
21
22
23
24
25
...
76
77
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
